NephRx Corporation announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients. Separately, NephRx announced that it has been awarded a total of $488,000 in two federal Qualifying Therapeutic Discovery Project (QTDP) grants...
More...
More...